|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
11,450,000 |
Market
Cap: |
10.65(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$0.2893 - $1.35 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Monopar Therapeutics is a biopharmaceutical company focused on developing proprietary therapeutics for cancer patients. Co.'s compounds in development: Validive®, a Phase 2b/3 clinical stage, mucoadhesive buccal tablet for the prevention of radiation induced severe oral mucositis in oropharyngeal cancer patients; camsirubicin, a Phase 1b clinical stage analog of doxorubicin engineered specifically to retain anticancer activity while minimizing toxic effects on the heart; MNPR-101, a preclinical stage uPAR-targeted antibody being developed as a radioimmunotherapeutic and companion diagnostic for cancers and COVID-19; and an early stage camsirubicin analog, MNPR-202, for various cancers.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
60,000 |
60,000 |
60,000 |
76,053 |
Total Buy Value |
$41,531 |
$41,531 |
$41,531 |
$91,190 |
Total People Bought |
1 |
1 |
1 |
1 |
Total Buy Transactions |
5 |
5 |
5 |
7 |
Total Shares Sold |
0 |
0 |
0 |
0 |
Total Sell Value |
$0 |
$0 |
$0 |
$0 |
Total People Sold |
0 |
0 |
0 |
0 |
Total Sell Transactions |
0 |
0 |
0 |
0 |
End Date |
2024-03-09 |
2023-12-07 |
2023-06-08 |
2022-06-08 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Tsuchimoto Kim R |
Chief Financial Officer |
|
2021-12-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,221 |
4,690 |
|
- |
|
Robinson Chandler |
Chief Executive Officer |
|
2021-12-31 |
4 |
D |
$3.21 |
$4,378 |
D/D |
(1,364) |
29,336 |
|
- |
|
Robinson Chandler |
Chief Executive Officer |
|
2021-12-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,941 |
30,700 |
|
- |
|
Starr Christopher M |
|
|
2021-12-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
751 |
4,294 |
|
- |
|
Klausner Arthur J |
|
|
2021-12-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
751 |
9,294 |
|
- |
|
Brown Michael J |
|
|
2021-12-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
751 |
214,294 |
|
- |
|
Mazar Andrew Paul |
Chief Scientific Officer |
|
2021-12-31 |
4 |
D |
$3.21 |
$1,785 |
D/D |
(556) |
19,724 |
|
- |
|
Mazar Andrew Paul |
Chief Scientific Officer |
|
2021-12-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,606 |
20,280 |
|
- |
|
Starr Christopher M |
|
|
2021-09-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
751 |
3,543 |
|
- |
|
Brown Michael J |
|
|
2021-09-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
751 |
213,543 |
|
- |
|
Klausner Arthur J |
|
|
2021-09-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
751 |
8,543 |
|
- |
|
Robinson Chandler |
Chief Executive Officer |
|
2021-09-30 |
4 |
D |
$4.87 |
$5,625 |
D/D |
(1,155) |
26,759 |
|
- |
|
Robinson Chandler |
Chief Executive Officer |
|
2021-09-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,941 |
27,914 |
|
- |
|
Mazar Andrew Paul |
Chief Scientific Officer |
|
2021-09-30 |
4 |
D |
$4.87 |
$2,294 |
D/D |
(471) |
18,674 |
|
- |
|
Mazar Andrew Paul |
Chief Scientific Officer |
|
2021-09-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,606 |
19,145 |
|
- |
|
Anderson Raymond |
|
|
2021-09-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
751 |
4,543 |
|
- |
|
Tsuchimoto Kim R |
Chief Financial Officer |
|
2021-09-30 |
4 |
D |
$4.87 |
$2,060 |
D/D |
(423) |
3,469 |
|
- |
|
Tsuchimoto Kim R |
Chief Financial Officer |
|
2021-09-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,221 |
3,892 |
|
- |
|
Brown Michael J |
|
|
2021-06-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
752 |
212,792 |
|
- |
|
Tsuchimoto Kim R |
Chief Financial Officer |
|
2021-06-30 |
4 |
D |
$5.89 |
$4,847 |
D/D |
(823) |
2,671 |
|
- |
|
Tsuchimoto Kim R |
Chief Financial Officer |
|
2021-06-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,442 |
3,494 |
|
- |
|
Klausner Arthur J |
|
|
2021-06-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
752 |
7,792 |
|
- |
|
Starr Christopher M |
|
|
2021-06-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
752 |
2,792 |
|
- |
|
Mazar Andrew Paul |
Chief Scientific Officer |
|
2021-06-30 |
4 |
D |
$5.89 |
$5,548 |
D/D |
(942) |
17,539 |
|
- |
|
Mazar Andrew Paul |
Chief Scientific Officer |
|
2021-06-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,212 |
18,481 |
|
- |
|
161 Records found
|
|
Page 5 of 7 |
|
|